GSK3186899 / GSK - LARVOL DELTA

Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects (clinicaltrials.gov) - P1; N=45; Terminated; Sponsor: GlaxoSmithKline; Suspended ➔ Terminated; Temporary halt following emergence of nonclinical data with a non-GSK asset. No data to preclude continuation but decision to terminate after strategic review.

Clinical • Trial termination • Infectious Disease • CRP

A Molecular Modeling Approach to Identify Potential Antileishmanial Compounds Against the Cell Division Cycle (cdc)-2-Related Kinase 12 (CRK12) Receptor of Leishmania donovani. (PubMed, Biomolecules) - "The molecular docking studies revealed two compounds NANPDB1406 and NANPDB2581 with binding affinities of -9.5 and -9.2 kcal/mol, respectively, against LdCRK12 which were higher than those of the known inhibitors and drugs, including GSK3186899, amphotericin B, miltefosine, and paromomycin...The molecules were pharmacologically profiled as druglike with inconsequential toxicity. The identified molecules have scaffolds that could form the backbone for fragment-based drug design of novel leishmanicides but warrant further studies to evaluate their therapeutic potential."

Journal • Infectious Disease • CDK1

Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects (clinicaltrials.gov) - P1; N=54; Suspended; Sponsor: GlaxoSmithKline; Trial completion date: May 2021 ➔ Mar 2022; Trial primary completion date: May 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • CRP

Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects (clinicaltrials.gov) - P1; N=54; Suspended; Sponsor: GlaxoSmithKline; Trial completion date: May 2020 ➔ May 2021; Trial primary completion date: May 2020 ➔ May 2021

Clinical • Trial completion date • Trial primary completion date • CRP

Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects (clinicaltrials.gov) - P1; N=54; Suspended; Sponsor: GlaxoSmithKline; Recruiting ➔ Suspended

Clinical • Trial suspension